Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Les effets du stress opérationnel répété et d’une récupération limitée sur la capacité de résilience (REP DEF)

This longitudinal study will examine the effects of repeated bouts of operational stress and limited recovery on integrated MPS, whole-body protein balance, iron absorption, and aerobic performance. Following baseline characterization measures, active adults (n=24) representative of normal weight phenotype (NW; n=12) and overweight phenotype (OW; n=12) will complete a 48h balance phase preceding two rounds of repeated 72h energy deficit exposure each immediately followed by a 48h recovery phase. NW cutoff will be defined ≤ 22% body fat for males and ≤ 32% body fat for females. OW cutoff will be defined as >22% body fat for males and >32% body fat for females. These body composition cutoffs are informed by the maximum allowable percent body fat standards outlined in current Army Regulation 600-9. Additional details for determining % body fat are outlined in the experimental procedures section of the protocol.

Aperçu de l'étude

Description détaillée

Operational stress inherent of military training and operations is largely unavoidable and jeopardizes Warfighter readiness and performance. Operational stressors, including high physical activity, severe energy deficiency, and restricted sleep, challenge Warfighter resilience. The characterization of physiological factors contributing to maintained or declining resilience during repeated stress exposures with limited recovery is therefore required to enable development of new, targeted interventions that maintain or enhance resilience. Previous efforts have characterized the regulation of physiological status, including muscle recovery and endocrine function, during operational stress. However, no studies have directly assessed the effects of limited recovery (i.e., 48h) on physiological and performance decrements associated with repeated operational stress or resilience capacity. It is possible that repeated missions and limited recovery will drive progressive declines of physiological status and performance. The effects of operational stress on nutrition status also negatively impact readiness and performance. Absorption of key dietary nutrients, such as iron, is required to sustain nutritional status; and iron status, specifically, has been associated with performance declines. Laboratory and field-based studies from our group have shown declines in iron status and absorption following a single simulated sustained operation. However, no studies have directly assessed the effects of limited recovery (i.e., 48h) on physiological and performance decrements associated with repeated operational stress or resilience capacity. It is possible that repeated missions and limited recovery will drive progressive declines of physiological status and performance. Beyond characterizing the effects of repeated cycles of operational stress, there is potential value in determining whether body composition phenotypes (i.e., "energy deficiency-sensitive" and "energy deficiency-resistant") may modulate resilience during energy deficiency. Should phenotype-based differences be determined and suggest more beneficial/resilient vs. less beneficial/less resilient body composition phenotypes, guidance to maintain or interventions to achieve optimal body composition are potential individualized strategies to enhance resilience.

This longitudinal study will examine the effects of repeated operational stress and limited recovery on integrated muscle protein synthesis, whole-body protein balance, iron absorption, and aerobic performance. Adults (n=24) representative of normal weight and overweight phenotype (n=12/phenotype) will complete a 48h balance phase preceding two repeated rounds of 72h energy deficit (increased physical activity and reduced dietary intake) with sleep restriction followed by a 48h recovery phase.

Type d'étude

Interventionnel

Inscription (Réel)

27

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Massachusetts
      • Natick, Massachusetts, États-Unis, 01760
        • US Army Research Institute of Environmental Medicine

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

17 ans à 39 ans (Enfant, Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Men and women aged 18 - 39 years (17 - 39 years if military personnel)
  • Weight stable in the past 2 months (± approximately 5 kg)
  • Healthy without evidence of chronic illness or musculoskeletal injury as determined by the USARIEM Office of Medical Support and Oversight (OMSO) or home duty station medical support (HMS)
  • Functional exercise (i.e., step ups, box jumps, body mass movements) and/or aerobic exercise trained defined by self-report as performing ≥ 2 sessions/wk for previous 6 months
  • Willing to refrain from alcohol, smoking any nicotine product (includes e-cigarettes); vaping, chewing tobacco, caffeine not provided in the study, and dietary supplement use throughout the dietary interventions
  • Biological females must be on sustained (i.e., approximately >3 months) oral/hormonal contraceptive use which acts to maintain continuous hormonal levels (i.e., contains low-dose estrogen/progesterone with no oral placebos, hormonal IUD)
  • Supervisor approval for federal civilian employees and non-HRV active duty military personnel)

Exclusion Criteria:

  • Musculoskeletal injuries that compromise exercise capability as determined by OMSO or HMS
  • Metabolic or cardiovascular abnormalities, sleep disorders (i.e., sleep apnea) gastrointestinal disorders (e.g., kidney disease, diabetes, cardiovascular disease, etc.) as determined by OMSO or HMS
  • Abnormal or problems with blood clotting as determined by OMSO or HMS
  • History of complications with lidocaine or similar local anesthetic analogue
  • Present condition of alcoholism, anabolic steroids, or other substance abuse issues
  • Blood donation within 8-wk of beginning or completing study blood draws
  • Current diagnosis of Anemia (hemoglobin < 13 g/dL for males, hemoglobin < 12 g/dL for females) and Sickle Cell Anemia/Trait as determined by OMSO or HMS
  • Pregnant, trying to become pregnant, and/or breastfeeding (results of urine pregnancy test or self-report for breastfeeding will be obtained before body composition testing)
  • Claustrophobia or discomfort related to having enclosed equipment around the head
  • Unwillingness or inability to consume study diets or foods provided due to personal preference or food allergies/sensitivities
  • Unwillingness or inability to adhere to study exercise restrictions and prescriptions

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active adults representative of overweight phenotype

Active adults representative of overweight phenotype will complete a 48h balance phase followed by two rounds of repeated 72h energy deficit exposure, each immediately followed by a 48h recovery phase.

Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.

Comparateur actif: Active adults representative of normal weight phenotype

Active adults representative of normal weight phenotype will complete a 48h balance phase followed by two rounds of repeated 72h energy deficit exposure, each immediately followed by a 48h recovery phase.

Intervention consists of a 48 hour energy balance phase preceding two rounds of repeated 72 hour energy deficit exposure each immediately followed by a 48h recovery phase. Balance and recovery phases will meet 100% of baseline energy requirements. Energy deficit phases will include an approximate 60% energy deficit of total daily energy requirements achieved through both a reduction in dietary intake and increased energy expenditure through physical activity.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Integrated muscle protein synthesis
Délai: Days 1-13

deuterium oxide stable isotope

Days 1-13
Whole-body protein balance
Délai: 24 hours

15N alanine stable isotope

24 hours
Iron Absorption
Délai: 24 hours

57-Fe dissolved in water

24 hours

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jess A Gwin Principal Investigator, PhD, United States Army Research Institute of Environmental Medicine

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

2 mai 2025

Achèvement primaire (Réel)

10 avril 2026

Achèvement de l'étude (Réel)

10 avril 2026

Dates d'inscription aux études

Première soumission

14 janvier 2025

Première soumission répondant aux critères de contrôle qualité

14 janvier 2025

Première publication (Réel)

20 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 24-33HC
  • MO240019 (Autre subvention/numéro de financement: Military Operational Medicine Research Program)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner